September 25, 2022

Medical Trend

Medical News and Medical Resources

The booster of COVID-19 vaccine by Sanofi and GlaxoSmithKline effective against Omicron

The booster of COVID-19 vaccine by Sanofi and GlaxoSmithKline effective against Omicron



 

The booster of COVID-19 vaccine by Sanofi and GlaxoSmithKline effective against Omicron

In this vaccine race, Sanofi and GlaxoSmithKline, which have fallen behind, are catching up with their boosters.

Global vaccine maker Sanofi said on Monday that the COVID-19 booster shot jointly developed with GlaxoSmithKline showed a strong immune response in a phase three trials.

 

The booster of COVID-19 vaccine by Sanofi and GlaxoSmithKline effective against Omicron

 

 

The booster was shown to be safe and well tolerated in a study of 247 people, according to the company.

 

Sanofi said the booster needle has the potential to prevent multiple variants, including Omicron Ba1 and Ba2.

In subjects who had received two doses of the mRNA vaccine, the booster shot increased antibodies against Ba 1 by 40-fold.

 

In addition, the booster produced better results than the booster (third dose) from Pfizer and BioNtech, which jointly developed a vaccine that doubled the amount of neutralizing Ba1 and Ba2 antibodies.

 

Thomas Triomphe, executive vice president of vaccines at Sanofi, said that as the new coronavirus continues to evolve and weaken immunity, certain groups of people may need additional booster shots.

 

However, now that the world has transitioned to a post-epidemic era, and major manufacturers have segmented most of the vaccine market, the experimental results from Sanofi and GlaxoSmithKline seem to be overdue.

 

After the outbreak of the COVID-19 epidemic, global vaccine manufacturers have launched a competition to develop a COVID-19 vaccine. Sanofi and GlaxoSmithKline, the world’s two largest vaccine makers, are losing out in this race.

 

Sanofi has also tried to develop an mRNA vaccine and achieved some results in the experiment, but because it lags behind its competitors in deploying new technologies, the vaccine has missed the best time to enter the market.

 

Therefore, in September last year, Sanofi announced that it would abandon the research and development of mRNA candidate COVID-19 vaccines, and instead cooperate with GlaxoSmithKline to develop recombinant protein COVID-19 vaccines (with adjuvant).

The former is responsible for developing the vaccine, and the latter provides an adjuvant that increases its efficacy.

 

It is worth mentioning that protein COVID-19 vaccines may have advantages over mRNA.

According to a previous report by Science and Technology Daily, the protein COVID-19 vaccine is simple to manufacture, has low cost, and has few side effects.

Therefore, it is expected to not only fill the global COVID-19 vaccination gap, but also further curb the development momentum of the COVID-19 epidemic.

 

In February, more than a year after the vaccine developed by BioNTech/Pfizer, Moderna, Oxford/ AstraZeneca had been approved, Sanofi and GSK filed for regulatory approval for their first Covid-19 vaccine. The application has been approved, and the application is still in progress.

 

In addition, at a time when the global COVID-19 vaccine is facing a surplus, even if the vaccine developed by Sanofi and GlaxoSmithKline is approved, it will still face more intense competition, especially in the Omicron vaccine.

 

Moderna announced last week that it has developed a new vaccine that is effective against Omicron and will launch it in the summer.

Separately, Pfizer and BioNTech are expected to release data on their Omicron-specific vaccine in the coming weeks, according to the media.

 

 

The booster of COVID-19 vaccine by Sanofi and GlaxoSmithKline effective against Omicron

(source:internet, reference only)


Disclaimer of medicaltrend.org